Search results for " Drug"

showing 10 items of 3138 documents

The diagnosis of and treatment recommendations for anxiety disorders.

2014

Anxiety disorders (panic disorder/agoraphobia, generalized anxiety disorder, social phobia, and specific phobias) are the most common mental illnesses. For example, the 12-month prevalence of panic disorder/agoraphobia is 6%.This guideline is based on controlled trials of psychotherapy and pharmacotherapy, retrieved by a systematic search for original articles that were published up to 1 July 2013. Experts from 20 specialty societies and other organizations evaluated the evidence for each treatment option from all available randomized clinical trials and from a synthesis of the recommendations of already existing international and German guidelines.403 randomized controlled trials were eval…

medicine.medical_specialtymedicine.medical_treatmentMEDLINElaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled triallawRisk FactorsmedicineHumansIntensive care medicinePsychiatryPsychodynamic psychotherapyPsychotropic Drugsbusiness.industryGeneral MedicineGuidelineClinical Practice GuidelineAnxiety Disorders030227 psychiatry3. Good healthCognitive behavioral therapyPsychotherapyNeurologyPractice Guidelines as TopicAnxietymedicine.symptomReuptake inhibitorbusiness030217 neurology & neurosurgeryDeutsches Arzteblatt international
researchProduct

The long and winding road of non steroidal antinflammatory drugs and paracetamol in cancer pain management: A critical review

2013

The aim of this review was to assess the value of NSAIDs and paracetamol in patients with cancer pain to update a previous review performed ten years ago on this topic. The approach was analytic and based on clinical considerations, rather than on raw evidence, which often does not provide useful information in clinical practice. Both published reports from an extensive search of electronic data bases were collected from January 2001 to December 2011. A free-text search method was used including the following words and their combination: “Anti-inflammatory drugs OR paracetamol OR acetaminophen” AND/OR “cancer pain”. Any randomized-controlled trial was considered. Thirteen reports fulfitted …

medicine.medical_specialtymedicine.medical_treatmentSettore MED/41 - AnestesiologiaPainlaw.inventionPain ladderRandomized controlled triallawNeoplasmsmedicineHumansPain ManagementCancer painIntensive care medicineAcetaminophenbusiness.industryPatient-controlled analgesiaAnti-Inflammatory Agents Non-SteroidalanalgesiaHematologyAnalgesics Non-NarcoticAcetaminophenKetorolacParacetamolTreatment OutcomeOncologyOpioidAnesthesiaElectronic dataAnti-inflammatory drugCancer painbusinessCancer pain; Anti-inflammatory drugs; Paracetamol; analgesiamedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Ultrasound-induced blood clot dissolution without a thrombolytic drug is more effective with lower frequencies.

2004

<i>Background and Purpose:</i> Therapeutic ultrasound as stand-alone therapy or in combination with rt-PA has proven to be an effective measure for recanalisation of acute vessel occlusion in different in vitro and in vivo studies. Uncertainty still exists concerning the optimal frequency and intensity with regard to the thrombolytic efficacy of ultrasound. The purpose of this study was a direct comparison of different ultrasound frequencies, when otherwise using identical measurement settings and parameters. <i>Methods:</i> Ultrasound-induced dissolution of fresh human blood clots was studied in a flow system using low-frequency continuous wave ultrasound of 20, 40 …

medicine.medical_specialtymedicine.medical_treatmentVessel occlusionThrombolytic drugInternal medicinemedicineHumansThrombolytic TherapyUltrasonicsStrokeBlood CoagulationUltrasonographyTherapeutic ultrasoundbusiness.industryUltrasoundAnticoagulantsThrombolysisFrequency dependencemedicine.diseaseRecombinant ProteinsSurgeryBloodNeurologyCalibrationCardiologyNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessCerebrovascular diseases (Basel, Switzerland)
researchProduct

Impact of a physician-targeted letter on opioid prescribing.

2020

We study the effect of a physician-targeted nudge letter on opioid prescribing. In May 2017, the Social Insurance Institution of Finland sent a personal information letter to all physicians who had issued a prescription containing at least 100 tablets of paracetamol-codeine combination to a new patient. The aim of the letter was to draw the physicians’ attention to their prescribing practices and to decrease the size of the first codeine prescription. Using individual level register data and a difference-in-differences strategy, we estimate that the letter decreased the average number of tablets purchased by new patients by 12.5 percent and the probability of a first purchase being at least…

medicine.medical_specialtyprescription drugslääkemääräyksetOpioid prescribingSocial insuranceinformation letter03 medical and health sciencesopioiditdifference-in-differencesPhysicians0502 economics and businessmedicinelääketurvallisuusHumans050207 economicsMedical prescriptionlääkäritPractice Patterns Physicians'Finlandohjeetbusiness.industry030503 health policy & servicesHealth Policy05 social sciencesCodeineKansaneläkelaitospalautePublic Health Environmental and Occupational HealthIndividual levelKELADifference in differencesreseptilääkkeetAnalgesics OpioidlääkkeetRegister dataFamily medicineopioid prescribing0305 other medical sciencebusinessPersonally identifiable informationmedicine.drugJournal of health economics
researchProduct

Are biological drugs effective and safe in older severe asthmatics?

2019

Introduction: The treatment of asthma in older ages follows the recommendations of international guidelines for the management of asthma in younger ages, although older age has always represented an exclusion criterion for eligibility to pharmacological trials. This poses a clinical challenge when deciding whether elderly severe asthmatics are candidates for biological drugs. Areas covered: The current article has a narrative structure to review the current literature on efficacy and safety of novel pharmacological drugs against immunoglobulins and interleukins that mediate and orchestrate the main inflammatory pathways in severe asthma, in order to explore whether older subjects (i.e. >…

medicine.medical_specialtypulmonary eosinophilia/drug therapyeducationImmunoglobulinsmonoclonal030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentSeverity of Illness IndexBiological drugs03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineSeverity of illnessImmunoglobulinHumansMedicineAnti-Asthmatic AgentPharmacology (medical)Age FactorAnti-Asthmatic AgentsAsthmaAgedRandomized Controlled Trials as TopicBiological ProductsAsthma/drug therapybiologyhumanizedbusiness.industryInterleukinsAge FactorsGeneral MedicineInterleukinmedicine.diseaseAsthmarespiratory tract diseasesantibodie030220 oncology & carcinogenesisMonoclonalPractice Guidelines as Topicbiology.proteinBiological Productanti-asthmatic agents/pharmacologyAntibodybusinessHuman
researchProduct

INHIBITION OF CELLULAR GROWTH AND STEROID 11β-HYDROXYLATION INRAS-TRANSFORMED ADRENOCORTICAL CELLS BY THE FUNGAL TOXINS BETICOLINS

1996

Abstract The proliferation of GM16 and 4CDTras-transformed newborn rat adrenocortical (RTAC) cells and Y1 mouse adrenal tumor cells was inhibited by beticolins, the fungal toxins extracted fromCercospora beticola, at submicromolar concentrations in a dose-dependent manner. Inhibitory concentrations for half the maximum inhibition were 150, 75 and 25 n M for beticolin-1 and 230, 150 and 50 n M for beticolin-2 in GM16, 4CDT and Y1 cells respectively. Beticolins strongly inhibited the production of 11β-hydroxysteroids on the second and third days of treatment in a dose-dependent manner between 0.1 and 1 μ M . Beticolins were shown by confocal microscopy to be localized in cytoplasmic organelle…

medicine.medical_treatmentAdrenal Gland NeoplasmsBiologyTransfectionHeterocyclic Compounds 4 or More RingsSteroidlaw.inventionHydroxylationMiceStructure-Activity Relationshipchemistry.chemical_compoundConfocal microscopylawOrganelleTumor Cells CulturedmedicineAnimalsCells CulturedHydroxysteroidsMicroscopy ConfocalDose-Response Relationship DrugCell growthCell BiologyGeneral MedicineMycotoxinsGrowth InhibitorsNeoplasm ProteinsRatsCell Transformation NeoplasticGenes rasAnimals NewbornchemistryBiochemistryCytoplasmAdrenal CortexSteroid 11-beta-HydroxylaseSignal transductionGrowth inhibitionCell DivisionCell Biology International
researchProduct

Clinical implications ofCYP3Apolymorphisms

2006

Due to their enormous substrate spectrum CYP3A4, -3A5 and -3A7 constitute the most important drug-metabolising enzyme subfamily in humans. CYP3As are expressed predominantly, but not exclusively, in the liver and intestine, where they participate in the metabolism of 45 - 60% of currently used drugs and many other compounds such as steroids and carcinogens. CYP3A expression and activity vary interindividually due to a combination of genetic and nongenetic factors such as hormone and health status, and the impact of environmental stimuli. Over the past several years, genetic determinants have been identified for much of the variable expression of CYP3A5 and -3A7, but not for CYP3A4. Using th…

medicine.medical_treatmentBiologyToxicologyBioinformatics030226 pharmacology & pharmacyGene Expression Regulation EnzymologicTacrolimusVariable Expression03 medical and health sciencesProstate cancer0302 clinical medicinemedicineCytochrome P-450 CYP3AHumansCYP3A5PharmacologyRegulation of gene expressionGeneticsPolymorphism GeneticCYP3A4General Medicinemedicine.diseaseTacrolimus3. Good healthIsoenzymesImmunosuppressive drug030220 oncology & carcinogenesisCyclosporineImmunosuppressive AgentsPharmacogeneticsExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Enantioselective determination of plasma protein binding of common amphetamine-type stimulants.

2021

Amphetamine-type stimulants (ATS) like amphetamine ('speed'), methamphetamine ('crystal meth') and 3,4-methylenedioxy-N-methylamphetamine (MDMA, 'ecstasy') represent some of the most frequently abused drugs worldwide. Another less frequently abused ATS is 4-fluoroamphetamine (4-FA). The enantiomers of these four compounds exhibit different pharmacokinetic and pharmacodynamic properties. According to the free drug theory, the pharmacological properties of a substance are dependent on its plasma protein binding (PPB). However, data on PPB of stimulant enantiomers in humans are rare or non-existent. Human plasma samples were spiked with racemic mixtures of the stimulants and subjected to ultra…

medicine.medical_treatmentClinical BiochemistryPharmaceutical ScienceTandem mass spectrometryAnalytical ChemistryPharmacokineticsTandem Mass SpectrometryDrug DiscoverymedicineHumansAmphetamineSpectroscopyChromatographyChemistryIllicit DrugsForensic toxicologyMDMAStereoisomerismMethamphetamineStimulantAmphetamineCentral Nervous System StimulantsEnantiomermedicine.drugChromatography LiquidProtein BindingJournal of pharmaceutical and biomedical analysis
researchProduct